CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
XPF-001 +1 moredrug
Likely dose
XPF-001 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00954356
NCT00954356Phase 2Completed

Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Safety, PK, & Efficacy of a Single Oral Dose of XPF-001 in the Treatment of Pain Related to Third Molar/Wisdom Tooth Extraction.

Xenon Pharmaceuticals Inc.·interventional·Posted Aug 7, 2009·Updated Jul 16, 2012

In Brief

A Phase 2 clinical trial evaluating XPF-001 and placebo for Dental Pain. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDental Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 7, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.9 years ago

Interventions

XPF-001drug

Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)

placebodrug

Single oral administration of 5 x 100 mg Placebo capsules.